Research progress of transcriptomics and proteomics in schizophrenia.
10.3760/cma.j.cn112150-20230310-00179
- Author:
Xin REN
1
;
Shu Min TAN
1
;
Jia Xiu LIU
1
;
Fei Ling JIANG
1
;
Xiao Bin WEI
1
Author Information
1. Department of Clinical Laboratory, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou 570208, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Proteomics/methods*;
Transcriptome;
Schizophrenia/genetics*
- From:
Chinese Journal of Preventive Medicine
2023;57(10):1704-1710
- CountryChina
- Language:Chinese
-
Abstract:
Schizophrenia is a severe psychiatric disorder with an unclear etiology and various clinical manifestations. The diagnosis and consequent treatment of schizophrenia mainly rely on clinical symptoms. Multiple risk sites associated with schizophrenia have been identified, yet objective indicators have not been found to facilitate clinical diagnosis and treatment of schizophrenia. The development of omics technology provides different perspectives on the etiology of schizophrenia and make the early identification, diagnosis and treatment of the disorder possible. This article summarizes the prevalence of schizophrenia, reviews the research results and shortcomings of transcriptomics and proteomics, as well as the latest achievements and prospects of multi-omics, aiming to reveal the use of omics in SZ, provide more comprehensive biological evidence to reveal the complex pathogenesis of schizophrenia and provide a theoretical basis for the early identification, accurate diagnosis, disease progression control, and prognosis improvement of schizophrenia.
